Year-Long test for new schizophrenia pill compares safety to existing treatment

NCT ID NCT04115319

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

Summary

This study aimed to see if a new, experimental schizophrenia medication called SEP-363856 is safe for people to take for a full year. It compared the drug's long-term safety and side effects to an already-approved medication, quetiapine XR. The trial involved 305 clinically stable adults with schizophrenia who took their assigned pill daily for 52 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Cerritos, California, 90703, United States
Research Site

Oakland, California, 94607, United States
Research Site

Oceanside, California, 92056, United States
Research Site

San Diego, California, 92103, United States
Research Site

Torrance, California, 90502, United States
Research Site

Miami, Florida, 33122, United States
Research Site

Miami Lakes, Florida, 33016, United States
Research Site

Atlanta, Georgia, 30328, United States
Research Site

Hoffman Estates, Illinois, 60169, United States
Research Site

Lincolnwood, Illinois, 60712, United States
Research Site

Shreveport, Louisiana, 71101, United States
Research Site

St Louis, Missouri, 63128, United States
Research Site

Las Vegas, Nevada, 89102, United States
Research Site

Cedarhurst, New York, 11516, United States
Research Site

Jamaica, New York, 11432, United States
Research Site

Rochester, New York, 14618, United States
Research Site

Charlotte, North Carolina, 28211, United States
Research Site

North Canton, Ohio, 44720, United States
Research Site

Brasov, 500079, Romania
Research Site

Bucharest, 041914, Romania
Research Site

Bucharest, 060222, Romania
Research Site

Bucharest, 41914,, Romania
Research Site

Iași, 700282, Romania
Research Site

Arkhangelsk, 163530, Russia
Research Site

Moscow, 127083, Russia
Research Site

Omsk, 644070, Russia
Research Site

Saint Petersburg, 188357, Russia
Research Site

Saint Petersburg, 190121, Russia
Research Site

Saint Petersburg, 192019, Russia
Research Site

Saint Petersburg, 195176, Russia
Research Site

Saint Petersburg, 199106, Russia
Research Site

Smolensk, 214031, Russia
Research Site

Stavropol, 357034, Russia
Research Site

Tomsk, 634014, Russia
Research Site

Yaroslavl, 150003, Russia
Research Site

Yekaterinburg, 620030, Russia
Research Site

Ivano-Frankivsk, 76011, Ukraine
Research Site

Kharkiv, 61068, Ukraine
Research Site

Kyiv, 03049, Ukraine
Research Site

Smila, 20708, Ukraine
Research Site

Ternopil, 46027, Ukraine
Research Site

Uzhhorod, 88000, Ukraine

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA